Thank you for standing by. My name is John, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Assertio Holdings third-quarter results conference call.
The company achieved an adjusted EBITDA of $5.3 million, primarily driven by reduced selling, general, and administrative expenses. Sales of Rolvedon remained stable, while Indocin sales faced ...
Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million Cash and Short-Term Investments of $88.6 Million LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE) ...
We believe the timeline for the Spectrum acquisition was rushed because Assertio’s leadership was aware that its own flagship product, Indocin, was at imminent risk of losing exclusivity and facing ...
You may be keeping tabs on your salt intake and clocking your steps, but did you know that certain everyday medications could be sneaking up on your blood %% ...
Q3 2024 Earnings Call Transcript November 11, 2024 Operator: Thank you for standing by. My name is John, and I’ll be your conference operator today. At this time, I would like to welcome everyone to ...
Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.